FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380482107> ?p ?o ?g. }

• W4380482107 endingPage "E503" @default.
• W4380482107 startingPage "E494" @default.
• W4380482107 abstract "<h3>Background</h3> Sodium–glucose cotransporter-2 (SGLT2) inhibitors are cardioprotective agents in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease (CVD). Since little is known about their uptake in atherosclerotic CVD, we examined SGLT2 inhibitor prescribing trends and identified potential disparities in prescribing patterns. <h3>Methods</h3> We conducted an observational study using linked population-based health data in Ontario, Canada, from April 2016 to March 2020 of patients aged 65 years or older with concomitant type 2 diabetes and atherosclerotic CVD. To examine prevalent prescribing of SGLT2 inhibitors (canagliflozin, dapagliflozin and empagliflozin), we constructed 4 cross-sectional yearly cohorts from Apr. 1 to Mar. 31 (2016/17, 2017/18, 2018/19 and 2019/20). We estimated prevalent SGLT2 inhibitor prescribing by year and by subgroups, and identified factors associated with SGTL2 inhibitor prescribing using multivariable logistic regression. <h3>Results</h3> There were 208 303 patients in our overall cohort (median age 74.0 yr [interquartile range 68.0–80.0 yr], 132 196 [63.5%] male). Although SGLT2 inhibitor prescribing increased over time, from 7.0% to 20.1%, statin prescribing was initially 10-fold higher and later threefold higher than SGLT2 inhibitor prescribing. In 2019/20, SGLT2 inhibitor prescribing was roughly 50% lower among those aged 75 years or older than among those younger than 75 years (12.9% v. 28.3%, <i>p</i> < 0.001) and in women than in men (15.3% v. 22.9%, <i>p</i> < 0.001). Age 75 years or older, female sex, history of heart failure and kidney disease, and low income were independent factors of lower SGLT2 inhibitor prescribing. Among physician specialists, visits to endocrinologists and family physicians were stronger factors of SGLT2 inhibitor prescribing than cardiologist visits. <h3>Interpretation</h3> We found that 1 in 5 patients with diabetes and atherosclerotic CVD were prescribed SGLT2 inhibitors in 2019/20, whereas statins were prescribed for 4 of every 5 patients. Although SGLT2 inhibitor prescribing increased over the study period, disparities in adoption by age, sex, socioeconomic status, comorbidities and physician specialty remained." @default.
• W4380482107 created "2023-06-14" @default.
• W4380482107 creator A5004859111 @default.
• W4380482107 creator A5011877915 @default.
• W4380482107 creator A5022468464 @default.
• W4380482107 creator A5030080832 @default.
• W4380482107 creator A5048366969 @default.
• W4380482107 creator A5061694233 @default.
• W4380482107 creator A5063504727 @default.
• W4380482107 creator A5063955986 @default.
• W4380482107 creator A5074746148 @default.
• W4380482107 creator A5075830583 @default.
• W4380482107 creator A5084232629 @default.
• W4380482107 creator A5086976936 @default.
• W4380482107 date "2023-05-01" @default.
• W4380482107 modified "2023-10-16" @default.
• W4380482107 title "Prescribing patterns and factors associated with sodium–glucose cotransporter-2 inhibitor prescribing in patients with diabetes mellitus and atherosclerotic cardiovascular disease" @default.
• W4380482107 cites W2070739968 @default.
• W4380482107 cites W2075543662 @default.
• W4380482107 cites W2075578416 @default.
• W4380482107 cites W2146264128 @default.
• W4380482107 cites W2626446274 @default.
• W4380482107 cites W2760307524 @default.
• W4380482107 cites W2802067770 @default.
• W4380482107 cites W2807046356 @default.
• W4380482107 cites W2885504738 @default.
• W4380482107 cites W2900413769 @default.
• W4380482107 cites W2902527999 @default.
• W4380482107 cites W2905966229 @default.
• W4380482107 cites W2939222610 @default.
• W4380482107 cites W3011650703 @default.
• W4380482107 cites W3021898772 @default.
• W4380482107 cites W3028391295 @default.
• W4380482107 cites W3036804145 @default.
• W4380482107 cites W3081830235 @default.
• W4380482107 cites W3088173406 @default.
• W4380482107 cites W3153561131 @default.
• W4380482107 cites W3160152094 @default.
• W4380482107 cites W3178245457 @default.
• W4380482107 cites W3190862815 @default.
• W4380482107 cites W3193297191 @default.
• W4380482107 cites W3213097216 @default.
• W4380482107 doi "https://doi.org/10.9778/cmajo.20220039" @default.
• W4380482107 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37311594" @default.
• W4380482107 hasPublicationYear "2023" @default.
• W4380482107 type Work @default.
• W4380482107 citedByCount "0" @default.
• W4380482107 crossrefType "journal-article" @default.
• W4380482107 hasAuthorship W4380482107A5004859111 @default.
• W4380482107 hasAuthorship W4380482107A5011877915 @default.
• W4380482107 hasAuthorship W4380482107A5022468464 @default.
• W4380482107 hasAuthorship W4380482107A5030080832 @default.
• W4380482107 hasAuthorship W4380482107A5048366969 @default.
• W4380482107 hasAuthorship W4380482107A5061694233 @default.
• W4380482107 hasAuthorship W4380482107A5063504727 @default.
• W4380482107 hasAuthorship W4380482107A5063955986 @default.
• W4380482107 hasAuthorship W4380482107A5074746148 @default.
• W4380482107 hasAuthorship W4380482107A5075830583 @default.
• W4380482107 hasAuthorship W4380482107A5084232629 @default.
• W4380482107 hasAuthorship W4380482107A5086976936 @default.
• W4380482107 hasBestOaLocation W43804821071 @default.
• W4380482107 hasConcept C119060515 @default.
• W4380482107 hasConcept C126322002 @default.
• W4380482107 hasConcept C134018914 @default.
• W4380482107 hasConcept C2775887513 @default.
• W4380482107 hasConcept C2777180221 @default.
• W4380482107 hasConcept C2777422806 @default.
• W4380482107 hasConcept C2777451236 @default.
• W4380482107 hasConcept C2779384505 @default.
• W4380482107 hasConcept C2908647359 @default.
• W4380482107 hasConcept C2910068830 @default.
• W4380482107 hasConcept C555293320 @default.
• W4380482107 hasConcept C71924100 @default.
• W4380482107 hasConcept C72563966 @default.
• W4380482107 hasConcept C99454951 @default.
• W4380482107 hasConceptScore W4380482107C119060515 @default.
• W4380482107 hasConceptScore W4380482107C126322002 @default.
• W4380482107 hasConceptScore W4380482107C134018914 @default.
• W4380482107 hasConceptScore W4380482107C2775887513 @default.
• W4380482107 hasConceptScore W4380482107C2777180221 @default.
• W4380482107 hasConceptScore W4380482107C2777422806 @default.
• W4380482107 hasConceptScore W4380482107C2777451236 @default.
• W4380482107 hasConceptScore W4380482107C2779384505 @default.
• W4380482107 hasConceptScore W4380482107C2908647359 @default.
• W4380482107 hasConceptScore W4380482107C2910068830 @default.
• W4380482107 hasConceptScore W4380482107C555293320 @default.
• W4380482107 hasConceptScore W4380482107C71924100 @default.
• W4380482107 hasConceptScore W4380482107C72563966 @default.
• W4380482107 hasConceptScore W4380482107C99454951 @default.
• W4380482107 hasIssue "3" @default.
• W4380482107 hasLocation W43804821071 @default.
• W4380482107 hasLocation W43804821072 @default.
• W4380482107 hasLocation W43804821073 @default.
• W4380482107 hasOpenAccess W4380482107 @default.
• W4380482107 hasPrimaryLocation W43804821071 @default.
• W4380482107 hasRelatedWork W1834805266 @default.
• W4380482107 hasRelatedWork W2199901734 @default.
• W4380482107 hasRelatedWork W2336452419 @default.

• next